Polyrizon Ltd. has finished the branding process for its PL‑14 allergy blocker, which will be sold under the new name NASARIX™. The product is built on the company’s proprietary Capture and Contain™ hydrogel platform, designed to form a physical barrier that blocks allergens and viruses when applied intranasally.
The PL‑14 program is still in the pre‑clinical stage, but the company’s recent in‑vitro studies, announced earlier in the month, showed the hydrogel’s ability to reduce allergen penetration by more than 80% compared with a standard comparator. The global allergen‑blocker market is projected to reach about $210 million by 2033, and Polyrizon’s technology could capture a share of that niche by offering a non‑invasive, reusable solution that differs from existing pharmaceutical or device approaches.
Polyrizon remains unprofitable, with losses that have grown over the past five years and no revenue to date. The company has disclosed that it is exploring revenue‑generating real‑asset investments as a way to diversify cash flow while it advances its pipeline. No new financial guidance has been issued, and the company’s valuation is modest, reflecting its early‑stage status.
CEO Tomer Izraeli said the NASARIX branding “reflects our commitment to commercial readiness and our focus on building a strong, recognizable identity in the allergy and respiratory health markets.” He added that the branding milestone is a key step toward the next clinical and regulatory milestones for PL‑14.
Investors have noted the company’s recent pre‑clinical successes and its strategic move into real‑asset investments, but the early‑stage nature of the PL‑14 program and the lack of revenue keep sentiment cautious. The branding announcement is viewed as a positive signal of progress, yet it is one of several updates that shape the company’s trajectory in a competitive, high‑risk biotech landscape.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.